NTUS - Natus Medical Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.33
+0.33 (+0.97%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close34.00
Open34.19
Bid27.00 x 800
Ask35.00 x 900
Day's Range33.77 - 34.48
52 Week Range22.25 - 34.89
Volume148,911
Avg. Volume163,482
Market Cap1.17B
Beta (5Y Monthly)0.70
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateFeb 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
  • GlobeNewswire

    Natus Reaffirms Fourth Quarter 2019 Guidance and will Present at the 38th Annual JP Morgan Healthcare Conference

    Natus Medical Incorporated (NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today reaffirmed fourth quarter 2019 guidance (previously released October 24, 2019) and announced that Jonathan Kennedy, President and Chief Executive Officer will present at the 38th Annual JP Morgan Healthcare Conference in San Francisco. As previously announced on October 24, 2019, the Company's fourth quarter 2019 revenue guidance is expected to be between $128.0 million and $132.0 million and non-GAAP earnings per share guidance is expected to be between $0.44 and $0.50. The Company’s non-GAAP earnings per share guidance, excludes charges of approximately $6.7 million for amortization expense associated with intangible assets from prior acquisitions, certain other expenses, and related tax effects for the fourth quarter 2019, which the Company anticipates will reduce GAAP earnings per share by approximately $0.19.

  • GlobeNewswire

    Natus Medical to Hold 2019 Fourth Quarter Financial Results Conference Call on February 6th

    Natus Medical Incorporated (NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2019 fourth quarter financial results after the close of the market on Thursday, February 6th. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 1227558. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 1227558.

  • GlobeNewswire

    Natus Medical Finalizes Transition of Peloton Business to Pediatrix Medical Group and Completes Signing of Strategic Agreement

    Natus Medical Incorporated (NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced that effective December 31, 2019 the Company has finalized and executed the previously announced transition of the Peloton hearing screening services business to Pediatrix Medical Group (“Pediatrix”). Pediatrix Medical Group, a MEDNAX, Inc. company, will manage all newborn hearing screening services for Peloton hospitals while Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business.

  • GlobeNewswire

    Natus Announces $50 Million Share Repurchase Program

    Natus Medical Incorporated (NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $50 million of the Company's common stock. The Company intends to use cash on hand, cash generated from operations, and our existing credit facilities to fund the share repurchase program. As of September 30, 2019, the Company had cash and cash equivalents of approximately $63 million and availability under an existing line of credit of $155 million.

  • Hedge Funds Love Natus Medical (NTUS) Way More Than These 4 Stocks
    Insider Monkey

    Hedge Funds Love Natus Medical (NTUS) Way More Than These 4 Stocks

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GlobeNewswire

    Natus Medical Announces Third Quarter 2019 Financial Results

    Third quarter revenue of $123.5 millionThird quarter GAAP earnings per diluted share of $0.25Third quarter non-GAAP earnings per diluted share of $0.36 PLEASANTON, Calif., Oct..

  • GlobeNewswire

    Natus Medical Announces Transition of Peloton Business to Pediatrix Medical Group and Signing of Strategic Agreement

    Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company signed a definitive agreement to transition its Peloton hearing screening services business to Pediatrix Medical Group (“Pediatrix”). After the completion of the transition, Pediatrix will manage all newborn hearing screening services for Peloton hospitals.  As part of the transition, Natus and Pediatrix have entered into a strategic agreement where Natus will provide its best-in-class ALGO screeners and supplies to Pediatrix to support its entire hearing screening business.  Upon completion of this transition, Pediatrix will provide hearing screening services to over 500 U.S. hospitals.

  • 3 Stocks to Play a Millennial Parent Boom
    Investopedia

    3 Stocks to Play a Millennial Parent Boom

    Spending on baby-related products is set to increases as more millennials start a family. Capitalize on the theme by trading these stocks.

  • GlobeNewswire

    Natus Medical to Hold 2019 Third Quarter Financial Results Conference all on October 24th

    Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2019 third quarter financial results after the close of the market on Thursday, October 24th. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 8582045. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 8582045.

  • Sleep Apnea Market Gains Momentum: 3 Stocks in Focus
    Zacks

    Sleep Apnea Market Gains Momentum: 3 Stocks in Focus

    Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.

  • GlobeNewswire

    Natus to Present at 2019 Wells Fargo Healthcare Conference

    PLEASANTON, Calif., Sept. 03, 2019 -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the.

  • GlobeNewswire

    Natus Expands the Supporting Community of Otoscan

    Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce today that Starkey Hearing Technologies is equipped to receive images from Otoscan® - a breakthrough digital ear scanning solution – as input to manufacture customized hearing aid solutions. “Today marks another important milestone for our customers and all of us at Natus,” says Austin Noll, Executive Vice President and Chief Commercial Officer at Natus. “The Otoscan community of supporting manufacturers is further expanded with the addition of Starkey Hearing Technologies, which represents an essential achievement for the future success of the product.